Holen Sie sich die Stockscreener-App
0.5331
10.48%
-0.0624
Handel nachbörslich:
.55
0.0169
+3.17%
Schlusskurs vom Vortag:
$0.5955
Offen:
$0.5754
24-Stunden-Volumen:
704.56K
Relative Volume:
0.73
Marktkapitalisierung:
$28.46M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-151.16M
KGV:
-0.1795
EPS:
-2.97
Netto-Cashflow:
$-130.08M
1W Leistung:
-25.36%
1M Leistung:
-48.24%
6M Leistung:
-69.01%
1J Leistung:
-95.06%
1-Tages-Spanne:
$0.5331
$0.597
1-Wochen-Bereich:
$0.5331
$0.72
52-Wochen-Spanne:
$0.5331
$17.82
Alx Oncology Holdings Inc Stock (ALXO) Company Profile
Firmenname
Alx Oncology Holdings Inc
Sektor
Branche
Telefon
650-466-7125
Adresse
323 ALLERTON AVENUE, SOUTH SAN FRANCISCO
Vergleichen Sie ALXO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ALXO
Alx Oncology Holdings Inc
|
0.5331 | 28.46M | 0 | -151.16M | -130.08M | -2.97 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.01 | 124.29B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
610.64 | 68.39B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
590.06 | 35.99B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
262.16 | 33.93B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
264.32 | 28.47B | 3.81B | -644.79M | -669.77M | -6.24 |
Alx Oncology Holdings Inc Stock (ALXO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-06 | Hochstufung | Jefferies | Hold → Buy |
| 2024-12-19 | Herabstufung | Jefferies | Buy → Hold |
| 2024-03-08 | Herabstufung | Stifel | Buy → Hold |
| 2023-12-08 | Hochstufung | Jefferies | Hold → Buy |
| 2021-12-22 | Herabstufung | Jefferies | Buy → Hold |
| 2021-09-30 | Eingeleitet | Stifel | Buy |
| 2021-05-05 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-04-06 | Eingeleitet | UBS | Buy |
| 2021-02-10 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-08-11 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-08-11 | Eingeleitet | Credit Suisse | Outperform |
| 2020-08-11 | Eingeleitet | Jefferies | Buy |
| 2020-08-11 | Eingeleitet | Piper Sandler | Overweight |
Alle ansehen
Alx Oncology Holdings Inc Aktie (ALXO) Neueste Nachrichten
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World
ALXO stock touches 52-week low at $0.65 amid market challenges - Investing.com Australia
Cantor Fitzgerald Raises Earnings Estimates for ALX Oncology - Defense World
ALXO stock plunges to 52-week low of $0.73 amid market challenges - Investing.com Australia
ALXO stock plunges to 52-week low of $0.73 amid market challenges By Investing.com - Investing.com South Africa
ALX Oncology Holdings (ALXO) Could Find a Support Soon, Here's Why You Should Buy the Stock Now - Yahoo Finance
Why ALX Oncology Holdings Inc. (ALXO) Soared on Thursday - MSN
ALXO stock touches 52-week low at $0.89 amid market challenges - Investing.com Australia
ALXO stock touches 52-week low at $0.89 amid market challenges By Investing.com - Investing.com South Africa
Insider Buying: Rekha Hemrajani Acquires 30,000 Shares of ALX On - GuruFocus.com
ALX Oncology Holdings: Balancing Growth Potential and Uncertainty with a Hold Rating - TipRanks
Stifel Nicolaus Lowers ALX Oncology (NASDAQ:ALXO) Price Target to $1.50 - Defense World
ALX Oncology (NASDAQ:ALXO) Earns “Buy” Rating from HC Wainwright - Defense World
Why the Global Cancer Market Could Surpass $900 Billion-And the Stocks Leading the Charge - The Malaysian Reserve
Why the Global Cancer Market Could Surpass $900 Billion--And the Stocks Leading the Charge - PR Newswire
Sun Valley buying at Canagold Resources (CCM) - The Globe and Mail
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Given Average Rating of “Moderate Buy” by Brokerages - Defense World
Jefferies Financial Group Upgrades ALX Oncology (NASDAQ:ALXO) to “Buy” - Defense World
Stifel cuts ALX Oncology stock target to $1.50, maintains hold By Investing.com - Investing.com Canada
Promising Developments in ALX Oncology’s Clinical Pipeline Justify Buy Rating - TipRanks
Jefferies raises ALX Oncology stock to buy, target to $3 By Investing.com - Investing.com South Africa
ALX Oncology Reports 2024 Financial Results and Updates - TipRanks
Micro-, Small-Cap Firms Dominate Market Rally - Insider Monkey
Alx Oncology Holdings Inc Files For Mixed Shelf Of Up To $364.1 Million -March 06, 2025 at 05:35 pm EST - Marketscreener.com
ALX Oncology Holdings Inc (ALXO) Q4 2024 Earnings: EPS of -$0.55 Beats Estimate, Revenue Matches Forecast - GuruFocus.com
ALX Oncology Holdings Inc reports results for the quarter ended December 31Earnings Summary - TradingView
ALX Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update - The Manila Times
ALX Oncology Reports Fourth Quarter and Full Year 2024 Financial Results - TradingView
ALX Oncology jumps as Jefferies upgrades on upside potential - MSN
ALX Oncology stock jumps as Jefferies upgrades(ALXO:NASDAQ) - Seeking Alpha
This Zscaler Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday - Benzinga India
ALX Oncology to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025 - Barchart
ALX Oncology Cuts 30% Workforce, Eliminates President And CSO Role Amid Pipeline Prioritization - Nasdaq
Jefferies Upgrades ALX Oncology to Buy From Hold, Adjusts Price Target to $3 From $2 - Marketscreener.com
Jefferies Upgrades ALX Oncology Holdings (ALXO) - Nasdaq
ALX Oncology Holdings: Undervalued with Promising Catalysts and Growth Opportunities - TipRanks
Jefferies raises ALX Oncology stock to buy, target to $3 - Investing.com
ALX Oncology announces workforce reduction and officer departure By Investing.com - Investing.com Australia
ALX Oncology announces workforce reduction and officer departure - Investing.com India
ALX Oncology Announces Workforce Reduction and Leadership Change - TipRanks
ALX Oncology to Cut Workforce by 30% to Support New Clinical Initiatives -March 05, 2025 at 11:04 am EST - Marketscreener.com
ALX Oncology Highlights Focused Evorpacept Development - GlobeNewswire
ALX Oncology Highlights Focused Evorpacept Development Plan, Clinical Progress and Corporate Updates at R&D Day Webcast Event - Yahoo Finance
ALXO stock plunges to 52-week low, touches $0.96 By Investing.com - Investing.com South Africa
ALXO stock plunges to 52-week low, touches $0.96 - Investing.com
ALX Oncology (ALXO) to Release Earnings on Thursday - MarketBeat
When Will ALX Oncology Share Its 2024 Financial Performance? Key Date for Biotech Investors - StockTitan
Finanzdaten der Alx Oncology Holdings Inc-Aktie (ALXO)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.23%
1.63%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):